ALKBH3 and Hodgkins lymphoma: Hodgkin lymphoma cells were found to have ALKBH3 hypermethylation of the promoter CpG island and its transcriptional silencing, which has also been linked to poor clinical outcomes in Hodgkin lymphoma patients [48].